Non-racemic MDMA
Non-racemic MDMA, also known by the developmental code names ALA-002 and AM-1002, are non-racemic mixtures of the MDMA (midomafetamine; "ecstasy") enantiomers (R)-MDMA and (S)-MDMA which are under development for the treatment of social phobia (social anxiety disorder; SAD), autistic spectrum disorder (ASD), and generalized anxiety disorder (GAD). ALA-002, which is under development by PharmAla Biotech for social phobia and autistic spectrum disorders, is a mixture of 70–80% (R)-MDMA and 20–30% (S)-MDMA. Conversely, AM-1002, which is under development by Arcadia Medicine for GAD, is a mixture of 90% (R)-MDMA and 10% (S)-MDMA. Based on animal studies, (R)-MDMA-preferring non-racemic MDMA mixtures show less hyperlocomotion, hyperthermia, hypertension, and neurotoxicity than racemic MDMA. ALA-002 is in phase 2 clinical trials for SAD and ASD as of 2026, whereas AM-1002 is in phase 1/2 trials for GAD as of 2026.